New hope for thyroid eye disease: phase 3 drug trial launches in china
NCT ID NCT07211776
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ZL-1109 for people with moderate to severe thyroid eye disease, a condition that causes eye bulging and discomfort. About 99 Chinese adults will receive either the drug or a placebo to see if it safely reduces eye bulging by at least 2 millimeters. The trial is double-blinded, meaning neither participants nor doctors know who gets the real treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE (TED) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site01001
RECRUITINGShanghai, China
-
Site01002
RECRUITINGHefei, China
-
Site01004
RECRUITINGFuzhou, China
-
Site01005
RECRUITINGLuoyang, China
-
Site01006
NOT_YET_RECRUITINGBeijing, China
-
Site01007
RECRUITINGGuangzhou, China
-
Site01008
RECRUITINGFoshan, China
-
Site01009
RECRUITINGBeijing, China
-
Site01010
NOT_YET_RECRUITINGBeijing, China
-
Site01011
NOT_YET_RECRUITINGDalian, China
-
Site01012
NOT_YET_RECRUITINGShenyang, China
-
Site01013
NOT_YET_RECRUITINGTianjin, China
-
Site01016
NOT_YET_RECRUITINGWuxi, China
-
Site01017
NOT_YET_RECRUITINGNanchang, China
-
Site01018
NOT_YET_RECRUITINGHangzhou, China
-
Site01019
NOT_YET_RECRUITINGZhengzhou, China
-
Site01020
NOT_YET_RECRUITINGChangsha, China
-
Site01022
NOT_YET_RECRUITINGChengdu, China
-
Site01023
NOT_YET_RECRUITINGTaiyuan, China
-
Site01024
RECRUITINGJinan, China
-
Site01025
NOT_YET_RECRUITINGXuzhou, China
-
Site01026
NOT_YET_RECRUITINGYangzhou, China
-
Site01027
RECRUITINGGuiyang, China
-
Site01028
NOT_YET_RECRUITINGXi'an, China
-
Site01029
NOT_YET_RECRUITINGBengbu, China
-
Site01030
NOT_YET_RECRUITINGZhengzhou, China
-
Site01031
RECRUITINGChongqing, China